Smith, Wally R.

Sickle cell disease

Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers

Hemoglobinopathies and Related DisordersHemoglobin structure and function

Cited by 1,501

Crizanlizumab for the prevention of pain crises in sickle cell disease.

Ataga, K. I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., Guthrie, T. H., Knight-Madden, J., Alvarez, O. A., Gordeuk, V. R., et al. (2017) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersBlood groups and transfusion

Cited by 914

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up

Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology

Hemoglobinopathies and Related DisordersBlood groups and transfusion

Cited by 486

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Telen, M. J., Wun, T., McCavit, T. L., De Castro, L. M., Krishnamurti, L., Lanzkron, S., Hsu, L. L., Smith, W. R., Rhee, S., Magnani, J. L., et al. (2015) · Blood

Hemoglobinopathies and Related DisordersBlood groups and transfusion

Cited by 211